<p>Fennec Pharmaceuticals Inc.（TSE:FRX - 獲取免費報告）在週三的交易中跌破了其 50 日移動平均線。該股票的 50 日移動平均線為 C$11.73，最低交易價為 C$10.60。Fennec Pharmaceuticals 的股票最後交易價為 C$10.60，成交量為 103 股。</p>
<p>獲取 <strong>Fennec Pharmaceuticals</strong> 的提醒：</p>
<h2>Fennec Pharmaceuticals 價格表現</h2>
<p>該公司的 50 日移動平均線為 C$11.73，200 日移動平均線也為 C$11.73。公司的流動比率為 7.80，速動比率為 10.17，負債權益比為-620.83。公司的市值為 C$3.6202 億，市盈率為-40.77，貝塔值為 2.51。</p>
<h2>Fennec Pharmaceuticals 的內部活動</h2>
<p>在其他新聞中，內部人士 Southpoint Capital Advisors Lp 於 10 月 9 日星期四出售了 20,609 股該公司的股票。股票以平均價格 C$12.89 出售，總交易額為 C$265,650.01。交易完成後，內部人士直接持有 4,010,100 股公司的股票，價值 C$51,690,189。此次交易使其持股減少了 0.51%。內部人士在過去三個月內出售了 68,889 股公司股票，價值$900,406。內部人士持有公司 16.20% 的股份。</p>
<h2>關於 Fennec Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Fennec Pharmaceuticals Inc 是一家臨牀階段的生物技術公司，主要從事研究和開發活動。該公司正在開發硫代硫酸鈉（STS），作為一種防止與鉑類化療相關的聽力損失的化療保護劑。其主要產品候選藥物是 PEDMARK，這是一種新型配方的硫代硫酸鈉，用於預防順鉑引起的聽力損失或兒童的耳毒性。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Fennec Pharmaceuticals</li>
<li>如何從成長投資中獲利</li>
<li>市場動量：三隻有望大幅突破的股票</li>
<li>什麼是澳大利亞證券交易所（ASX）</li>
<li>Casey’s General Stores 將繼續上漲的三大理由</li>
<li>投資便士股票需要了解的事項</li>
<li>黃金交叉警報：三隻具有重大上漲潛力的股票</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Fennec Pharmaceuticals 嗎？</h2>
<p>在考慮 Fennec Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Fennec Pharmaceuticals 並不在名單上。</p>
<p>雖然 Fennec Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

FENC

<p>Fennec Pharmaceuticals（TSE:FRX）的股票跌破了其 50 日移動平均線，最低交易價格為 10.60 加元。該股票的 50 日移動平均線為 11.73 加元。內部人士 Southpoint Capital Advisors 以 12.89 加元的價格出售了 20,609 股。Fennec 是一家臨牀階段的生物技術公司，正在開發硫代硫酸鈉以預防接受化療的兒童聽力損失。儘管分析師給予該股持有評級，但建議其他股票作為更好的投資選擇</p>

<p>Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of C$11.73 and traded as low as C$10.60. Fennec Pharmaceuticals shares last traded at C$10.60, with a volume of 103 shares traded.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals Inc.（TSE:FRX - 獲取免費報告）在週三的交易中跌破了其 50 日移動平均線。該股票的 50 日移動平均線為 C$11.73，最低交易價為 C$10.60。Fennec Pharmaceuticals 的股票最後交易價為 C$10.60，成交量為 103 股。</p>
</div><p>Get <strong>Fennec Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Fennec Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Fennec Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Fennec Pharmaceuticals 價格表現</h2>
</div><p>The firm has a fifty day moving average of C$11.73 and a 200 day moving average of C$11.73. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83. The company has a market capitalization of C$362.02 million, a P/E ratio of -40.77 and a beta of 2.51.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均線為 C$11.73，200 日移動平均線也為 C$11.73。公司的流動比率為 7.80，速動比率為 10.17，負債權益比為-620.83。公司的市值為 C$3.6202 億，市盈率為-40.77，貝塔值為 2.51。</p>
</div><h2>Insider Activity at Fennec Pharmaceuticals</h2>
<div class="lb-trans"><h2>Fennec Pharmaceuticals 的內部活動</h2>
</div><p>In other news, insider Southpoint Capital Advisors Lp sold 20,609 shares of the business's stock in a transaction that occurred on Thursday, October 9th. The shares were sold at an average price of C$12.89, for a total transaction of C$265,650.01. Following the completion of the transaction, the insider directly owned 4,010,100 shares of the company's stock, valued at C$51,690,189. The trade was a 0.51% decrease in their ownership of the stock. Insiders have sold 68,889 shares of company stock valued at $900,406 in the last three months. Insiders own 16.20% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，內部人士 Southpoint Capital Advisors Lp 於 10 月 9 日星期四出售了 20,609 股該公司的股票。股票以平均價格 C$12.89 出售，總交易額為 C$265,650.01。交易完成後，內部人士直接持有 4,010,100 股公司的股票，價值 C$51,690,189。此次交易使其持股減少了 0.51%。內部人士在過去三個月內出售了 68,889 股公司股票，價值$900,406。內部人士持有公司 16.20% 的股份。</p>
</div><h2>About Fennec Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Fennec Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals Inc 是一家臨牀階段的生物技術公司，主要從事研究和開發活動。該公司正在開發硫代硫酸鈉（STS），作為一種防止與鉑類化療相關的聽力損失的化療保護劑。其主要產品候選藥物是 PEDMARK，這是一種新型配方的硫代硫酸鈉，用於預防順鉑引起的聽力損失或兒童的耳毒性。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Fennec Pharmaceuticals</li>
<li>How to Profit From Growth Investing</li>
<li>Market Momentum: 3 Stocks Poised for Major Breakouts</li>
<li>What is the Australian Securities Exchange (ASX)</li>
<li>3 Reasons Casey’s General Stores Will Continue Trending Higher</li>
<li>What to Know About Investing in Penny Stocks</li>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Fennec Pharmaceuticals</li>
<li>如何從成長投資中獲利</li>
<li>市場動量：三隻有望大幅突破的股票</li>
<li>什麼是澳大利亞證券交易所（ASX）</li>
<li>Casey’s General Stores 將繼續上漲的三大理由</li>
<li>投資便士股票需要了解的事項</li>
<li>黃金交叉警報：三隻具有重大上漲潛力的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Fennec Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Fennec Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Fennec Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Fennec Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Fennec Pharmaceuticals 並不在名單上。</p>
</div><p>While Fennec Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Fennec Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Fennec Pharmaceuticals（TSE:FRX）的股價跌破了 50 日移動平均線 - 接下來會發生什麼？